United States Eventing Association

Estimates indicate up to 60 percent of lameness in the horse is related to end-stage degenerative joint disease (DJD), also known as osteoarthritis (OA). DJD can influence performance and significantly impact any horse—from top competitors and weekend warriors to aging seniors.

Mobility matters, so help keep your horse moving with healthy joints and smart healthcare. Lameness. A dreaded word. Uttering it means that your horse may be out of commission. Determining the cause can be challenging, which means treatment—and recovery—can be a long process.

From proven arthritis medications to nutritional supplements, understanding the differences among joint product types can make a real difference in your horse’s long-term mobility. Just like horses are similar but different, so are equine joint products. They’re created in different ways, approved for different uses and monitored differently for safety and effectiveness. Choosing the product (or products) right for your horse can be complex. The decision depends on a number of factors, like the condition affecting your horse’s joints, your horse’s severity of lameness or degenerative joint disease (DJD), the type of work your horse does, and the list goes on.

Adequan^® returns as The Official Joint Therapy Treatment of the USEA and Title Sponsor of the $60,000 Adequan^® USEA Advanced Final for 2022.

The 2021 USEA American Eventing Championships (AEC) presented by Nutrena Feeds is one of the most exciting events of the year thanks in great part to sponsor involvement. With the help of this year's amazing roster of sponsors, the AEC is proud to offer over $100,000 in prize money and numerous prizes to be awarded through sixth place across each of the 23 divisions! Many of this year’s AEC sponsors will be on-site at the Kentucky Horse Park throughout the duration of the 2021 Championships and will offer great goodies and some special offers for those in attendance this year.

The United States Eventing Association (USEA) is thrilled to announce the renewed partnership with longtime supporter American Regent Animal Health, maker of Adequan® i.m. (polysulfated glycosaminoglycan).

Active horses need healthy cartilage to maintain joint function. In joints with degenerative joint disease, also known as osteoarthritis, the complex process of cartilage repair is unable to keep up with damage. This video from Adequan explains the process of cartilage breakdown and how Adequan can help reduce inflammation, restore joint lubrication, repair cartilage, and reverse the disease cycle.

The United States Eventing Association (USEA) is excited to announce the renewed corporate partnership with longtime sponsor Adequan^® i.m. (polysulfated glycosaminoglycan) as “The Official Joint Therapy Treatment of the USEA.” American Regent Animal Health, manufacturer of Adequan®, has increased its support of the USEA to be able to offer unparalleled prize money in the Advanced division at the 2019 USEA American Eventing Championships (AEC).

The United States Eventing Association (USEA) would like to welcome back longtime sponsor Adequan^® i.m. (polysulfated glycosaminoglycan) as “The Official Joint Therapy Treatment of the USEA”, Title Sponsor of the USEA Gold Cup Series and Contributing Level Sponsor of the USEA American Eventing Championships (AEC).

Wondering what's been going on with the shortage of Adequan this year? Luitpold Pharmaceutical's Allyn Mann gives an update on what happened and when you can expect supplies to return to normal.